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Adenosine (Fig. 1) is an endogenous nucleoside composed of
adenine attached to a ribose. It is an essential compound of life
distributed in several mammalian tissues (Cacciari et al., 2005).
Adenosine was ﬁrst recognized as a physiologic regulator of
coronary vascular tone by Drury and Szent-Gyo¨rgyu (1929),
however it was until 1970 that Sattin and Rall showed that
adenosine regulates cell function via occupancy of speciﬁc
receptors on the cell surface (Hasko´ et al., 2007;Sattin and
Rall, 1970). Adenosine may either leave the intracellular space
by exocytosis, or may generate by the enzymatic breakdown of
extracellular ATP. ATP may also release from injured neurons
and glial cells by passing the damaged plasma membrane
(Tautenhahn et al., 2012).
The adenosine directly affects a variety of synaptic pro-
cesses, signaling pathways and plays an important role in the
regulation of several neurotransmitters in the central nervous
system (CNS). Unlike a classical neurotransmitter, adenosine
is neither stored in synaptic vesicles nor it acts exclusively on
synapses. Its release and uptake are mediated by bidirectional
nucleoside transporters whereby the direction of transport so-
lely depends on the concentration gradient between the cyto-
plasm and the extracellular space. Adenosine is therefore
considered as a neuromodulator affecting neural activity
through multiple mechanisms presynaptically by controlling
neurotransmitter release, postsynaptically by hyper or depolar-
izing neurons, and nonsynaptically mainly via regulatory ef-
fects on glial cells (Boison et al., 2012).
Moreover, it also has some characteristics of neurotrans-
mitter as adenosine-producing enzymes are present in syn-
apses. It exerts its actions through the interaction with
receptors and its actions can be blocked by speciﬁc antago-
nists. Its actions are terminated by an efﬁcient reuptake system
and a metabolizing system (Cacciari et al., 2005).
Adenosine plays a vital role in various physiological func-
tions. It is involved in the synthesis of nucleic acids, when
linked to three phosphate groups; it forms ATP, the integralN
N
N
N
O
HO
HO OH
NH2
Figure 1 Structure of adenosine.component of the cellular energy system. It produces various
pharmacological effects, both in periphery and in the central
nervous system, through an action on speciﬁc receptors local-
ized on cell membranes (Matsumoto et al., 2012).
Adenosine produced in hypoxic, ischemic, or inﬂamed envi-
ronments reduces tissue injury and promotes repair. The intra-
cellular production of adenosine is increased during hypoxia or
ischemia (Linden, 2005). During cellular stress, local intracel-
lular concentrations of adenosine increase followed by the ac-
tive transport of adenosine into the extracellular space and
subsequent activation of adenosine receptor (P1) subtypes
(Shukla and Mishra, 1995).
1.1. Adenosine formation and metabolism
Adenosine is an endogenous purine nucleoside constitutively
present at low concentrations in the extracellular space, which
is known to increase dramatically under metabolically stressful
conditions. The reason for the increase is related to the activa-
tion of an auto regulatory loop, the function of which is to
protect organs from injury following the initiating stressful
stimuli (Poolsa and Holgate, 2006). Adenosine is formed at
both intracellular and extracellular sites by two distinct path-
ways that involve two different substrates, namely AMP and
S-adenosyl homocysteine and transported across cell mem-
branes by nucleoside transporters (Zhou et al., 2009; Poulsen
and Quinn 1998; Livingston et al., 2004).
After intracellular reuptake, adenosine undergoes rapid
phosphorylation to AMP by adenosine kinase, or deamination
to inosine by adenosine deaminase (Fig. 2). These pathways
ensure the maintenance of intracellular adenosine concentra-
tions through a strict enzymatic control. So, it is clear that
there are essentially three systems that can account for inacti-
vation and/or removal of adenosine in tissues: adenosine
deaminase, kinase, and the uptake system (Fig. 2). Strategies
to increase local concentrations of adenosine have included
inhibition of enzymes responsible for the metabolic transfor-
mation of adenosine. Speciﬁcally, inhibitors of adenosine
deaminase (ADA) and adenosine kinase (AK) have received
considerable attention in an attempt to increase concentrations
of endogenous adenosine (Fig. 3). Inhibition of adenosine ki-
nase displays neuroprotective potential in areas as pain and
inﬂammation (Mark et al., 2007).
Under hypoxic conditions, the adenosine reaches high con-
centrations inside the cell through a cascade of enzymatic ac-
tions and leads to the release of adenosine into the
extracellular space through nucleoside transporters (Antonioli
et al., 2008).
The other major pathway that contributes to high extracel-
lular adenosine concentrations during metabolic stress is re-
lease and degradation of precursor adenine nucleotides
(ATP, ADP and AMP) by a cascade of ectonucleotidases,
which include CD39 (nucleoside triphosphate diphosphohy-
drolase) and CD73 (50-ectonucleotidase). Adenosine accumu-
Figure 3 Intracellular and extracellular balancing system of
adenosine.
Figure 4 Adenosine receptor model (Figure adapted from
Hitchinson et al., 2006).
Figure 2 Adenosine formation and catabolism.
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deaminase.
2. Adenosine receptors and their classiﬁcation
The extracellular purines e.g., adenosine, adenosine 50-diphos-
phate (ADP) and adenosine 50-triphosphate (ATP)] and pyrim-
idines [e.g., uridine 50-diphosphate (UDP) and uridine 50-
triphosphate (UTP)] mediate diverse biological effects via
cell-surface receptors termed as purinergic receptors. These
receptors were ﬁrst formally recognized by Burnstock et al.
in 1978. He classiﬁed purinoceptors into two subtypes: P1
and P2 receptors, based on their pharmacological properties
and molecular cloning (Ralevic and Burnstock, 1991). P1 puri-
noceptors recognize adenosine as principal natural ligand and
P2 receptors have broad natural ligand speciﬁcity, recognizing
ATP, ADP, UTP, UDP and some dinucleotides. The P1 and P2
receptor families are both further subdivided according to con-
vergent molecular, biochemical, and pharmacological evi-
dences (Matsumoto et al., 2012). These purinoceptors are
present in most organ systems in the body, and they play an
important role in contractile tone of various arteries includingcerebral arteries, thoracic aorta, mesenteric and femoral arter-
ies. All these receptors belong to class A family of G-protein
coupled receptor (GPCR) super-family (Fig. 4) (Go¨blyo¨s and
IJzerman, 2009).
Fig. 4 represents adenosine receptor model. The extracellu-
lar domains of the receptor protein comprise the N-terminus
and three extracellular loops while the intracellular domains
of the receptor protein comprise the C-terminus and three
intracellular loops (Hutchinson and Scammells, 2006). Based
on IUPHAR nomenclature and classiﬁcation rules P1 recep-
tors are also named adenosine receptors (after the endogenous
ligand), while the subtypes are named the A1, A2A, A2B and A3
subtypes, the subscripts (1, 2A, 2B and 3) representing classiﬁ-
cation neutral labels. Each of the subtypes has been character-
ized by molecular cloning, agonist activity proﬁle, antagonist
activity proﬁle, G protein-coupling and effector systems. The
adenosine receptors have been characterized completely allow-
ing determination of actual receptor protein primary se-
quences, which is fundamental to study receptor structure,
Table 1 Distribution and expression of adenosine receptors.
Expression
level
A1 receptors A2A receptors A2B receptors A3 receptors
High
expression
Brain (cortex,
hippocampus,
cerebellum), spinal cord,
eye, adrenal gland, atria
(Poulsen and Quinn,
1998)
Blood platelets,
olfactory bulb Spleen,
thymus, leukocytes
(Fredholm et al., 2002)
Cecum, colon, bladder
(Cacciari et al., 2005)
Testis (rat), mast cells
(rat) (Poulsen and
Quinn, 1998)
Intermediate
expression
Other brain regions,
skeletal muscles, liver,
kidney, adipose tissue
(Poulsen and Quinn,
1998)
Heart, lung, blood
vessels, peripheral nerves
(Fredholm et al., 2002)
Lung, blood vessels, eye,
mast cells (Cacciari
et al., 2005)
Cerebellum,
hippocampus (Poulsen
and Quinn, 1998)
Low
expression
Lungs (but probably
higher in bronchi),
pancreas (Poulsen and
Quinn, 1998)
Other brain regions
(Fredholm et al., 2002)
Adipose tissue, adrenal
gland, brain, kidney
(Cacciari et al., 2005)
Thyroid, most of brain
adrenal gland, spleen,
liver, kidney, heart
(Poulsen and Quinn,
1998)
248 S. Sachdeva, M. Guptafunction and regulation at the molecular level (Poulsen and
Quinn, 1998). Experimental evidence has been reported for
the existence of two different histidine residues at the active site
of the adenosine receptor, one of which is involved in binding
with agonists while the other binds with antagonists of adeno-
sine (Shukla and Mishra, 1995).
At present there are four established adenosine receptors in
humans that have been cloned consisting of the A1, A2A, A2B
and A3 receptors. Adenosine and its agonists act via these
receptors and are able to modulate the activity of adenylate cy-
clase, the enzyme responsible for increasing cyclic AMP
(cAMP). The different receptors have differential stimulatory
and inhibitory effects on this enzyme. Increased intracellular
concentrations of cAMP can suppress the activity of immune
and inﬂammatory cells (Livingston et al., 2004).
2.1. A1 adenosine receptors
A1R is the most abundant adenosine receptor and is densely
expressed throughout the CNS with high abundance in the
neocortex, cerebellum, hippocampus and the dorsal horn of
the spinal cord and are also found in adipose tissue, heart mus-
cle, inﬂammatory cells such as neutrophils (Table 1) (Town-
send-Nicholson et al., 1995; Olah and Stiles,1995).
Adenosine is the main agonist at this receptor class and these
receptors have a high afﬁnity for adenosine analogs substituted
at the N6 position e.g., L-N6-phenylisopropyladenosine (L-
PIA) (Livingston et al., 2004). A1 receptors mediate the inhibi-
tion of adenylate cyclase. A1 receptor activation can also inhi-
bit G-protein-coupled activation of voltage dependent Ca2+
channels and is reported to induce phospholipase C activation
(Yuzlenko and Kononowicz, 2006).
2.2. A2 adenosine receptors
In contrast to the A1 receptor, A2 receptor stimulation leads to
the activation of adenylate cyclase resulting in the elevation of
intracellular cAMP. A2 receptors are more widely distributed
than A1 receptors, being found in pre and postsynaptic nerve
terminals, mast cells, airway smooth muscle and circulatingleukocytes (Table 1). They bind adenosine with less afﬁnity
than A1 receptors and are preferentially stimulated by adeno-
sine analogs substituted at the 50-N position e.g., 50-N-ethyl-
carboxamideadenosine (NECA). A2 receptors are subdivided
into the A2A and A2B receptors, based on high and low afﬁnity
for adenosine, respectively (Livingston et al., 2004). A2ARs are
highly enriched in striatal neurons but lower levels are also ex-
pressed in neurons outside of the striatum and in glial cells
(Boison et al., 2012). Adenosine A2A receptors are abundant
in the caudate putamen, nucleus accumbens, and olfactory
tubercle in several species. In the caudate putamen, adenosine
A2A receptors are localized in several neurons and have been
shown to modulate the neurotransmission of c-aminobutyric
acid (GABA), acetylcholine, and glutamate. These actions of
the A2A adenosine receptor could contribute to motor behav-
ior. (Matasi et al., 2005). The A2A adenosine receptor signals
in the periphery and the CNS, with agonists explored as
anti-inﬂammatory drugs and antagonists explored for neuro-
degenerative diseases (Carlsson et al., 2010). In most cell types
the A2A subtype inhibits intracellular calcium levels whereas
the A2B potentiates them. The A2A receptor is therapeutic tar-
get for coronary vasodilation (adenosine agonist); and Parkin-
son’s disease (adenosine antagonist) (Yuzlenko and
Kononowicz, 2006; Fredholm et al., 2002). The A2A receptor
generally appears to inhibit mediator release from these im-
mune cells (Borrmann et al., 2009).
A2B receptors are highly expressed in gastrointestinal tract,
bladder, lung and on mast cells (Table 1). The A2B receptor,
although structurally closely related to the A2A receptor and
able to activate adenylate cyclase is functionally very different.
It has been postulated that this subtype may utilize signal
transduction systems other than adenylate cyclase because of
these functional differences (Livingston et al., 2004). Among
all the adenosine receptors, the A2B adenosine receptor is a
low afﬁnity receptor that is thought to remain silent under
physiological conditions and to be activated in consequence
of increased extracellular adenosine levels (Ryzhov et al.,
2008). Activation of A2B adenosine receptor can stimulate
adenylate cyclase and phospholipase C through activation of
Gs and Gq proteins, respectively. Coupling to mitogen acti-
Adenosine and its receptors as therapeutic targets: An overview 249vated protein kinases has also been described (Borrmann et al.,
2009).
It has been proposed that adenosine contributes to the
pathogenesis of inﬂammatory airways disease by acting on
the mast cell A2B receptor to enhance the release of pro-inﬂam-
matory mediators (Livingston et al., 2004).
2.3. A3 adenosine receptor
The A3 receptor is distributed widely, being found in the kid-
ney, testis, lung, mast cells, eosinophils, neutrophils, heart
and the brain cortex (Table 1) (Livingston et al., 2004). As with
the A1 receptor, stimulation of the A3 adenosine receptor leads
to inhibition of adenylate cyclase. It has also been shown to
stimulate directly phospholipases C and D. A3 receptor activa-
tion also results in the inﬂux of calcium and its release from
intracellular stores (Jacobson, 1998). The A3 receptor usually
exhibits large differences in structure, tissue distribution and
its functional and pharmacological properties between species
(Linden, 1994). A3 mediated degranulation of mast cells or
enhancement of allergen induced mast cell degranulation
may be important in animal models of allergic responses.
However, the A3 receptor is not present on human lung mast
cells. The presence of A3 receptors in human eosinophils and
macrophages suggests other mechanisms for the involvement
of A3 receptors in inﬂammatory conditions including asthma
(Livingston et al., 2004).
Although a subtype labeled as the adenosine A4 receptor
has been characterized, it seems that this particular subtype
may be a binding state of adenosine A2A receptors. The major-
ity of published data indicates that the direct vascular actions
of adenosine are mediated via the adenosine A1, A2A, or A2B
receptor subtypes (Tabrizchi and Bedi, 2001).
Adenosine A1 and A2A receptors are characterized by high
afﬁnity for adenosine, while A2B and A3 receptors show signif-
icantly lower afﬁnity for adenosine. Activation of adenosine
A1 receptors occurs at 0.3–3 nM concentration of adenosine,
adenosine A2A receptors at 1–20 nM, while adenosine A2B or
A3 receptor activation requires an agonist concentration largerTable 2 Therapeutic potential of adenosine receptor ligands.
Adenosine receptors Therapeutic role
Agonist A1 Atrioventricular no
supraventricular ta
A2A Respiratory disord
reperfusion injury,
hypertension, inﬂam
A2B Allergic reactions
A3 Cardiac ischemias,
Antagonists A1 Bradyarrhythmia a
inferior myocardial
cardiac arrest, card
rejection
A2A Parkinson’s disease
neurodegeneration
A2B Asthma, pulmonar
A3 Glaucoma, asthmathan 1 lM (Cieslak et al., 2008). Adenosine receptors are
attractive targets for therapeutic intervention of a wide range
of disorders, such as hypoxia, asthma, Parkinson’s disease,
and many others. Among the four subtypes, A2B receptor is
functionally active on both human airway smooth muscle cells
and lung ﬁbroblast cells, which is related to inﬂammation and
asthma (Fredholm et al., 2002).
3. Therapeutic target for various adenosine receptors
The therapeutic potential for adenosinewas ﬁrst evaluated in the
1930’s (Kaiser and Quinn, 1999). At that time its short plasma
half-life (3–6 s) limited any meaningful efﬁcacy measures. Inter-
estingly, the short half-life of adenosine has made it an ideal
compound for the treatment of supraventricular tachycardia,
for which use it has been approved (Belardinelli et al., 1995).
Adenosine receptors are involved in several diseases, for exam-
ple and most importantly, Parkinson’s disease, ischemia and
inﬂammation (Federico and Spalluto, 2012). The stimulation
of cell surface adenosine receptors (ARs) is largely responsible
for the broad variety of effects produced by adenosine through-
out several organ systems. Based on the widespread and fre-
quently beneﬁcial effects, attributed to the accumulation of
endogenously released adenosine, it has long been considered
that regulation of ARs has substantial therapeutic potential
(Moro et al., 2005). Adenosine, marketed by Fujisawa Health-
care Inc. as Adenocard, is one of the adenosine receptor ago-
nist approved for clinical use. Bolus administration of
adenosine has proven to be the therapy of choice for the termi-
nation of paroxysmal supraventricular arrhythmias (PSVT).
Adenosine is also marketed as Adenoscan for use in myocar-
dial perfusion imaging. Adenoscan is a pharmacological stress
agent used to increase coronary blood ﬂow for thallium-201
myocardial perfusion scintigraphy with patients who are unable
to exercise sufﬁciently (Hutchinson and Scammells, 2006).
A summary of novel targets for selective adenosine receptor
ligands is given in Table 2. The selective agonists are well ad-
vanced in clinical trials for the treatment of atrial ﬁbrillation,
pain, neuropathy, pulmonary and other inﬂammatoryReferences
de block and
chyarrhythmia
Ellenbogen et al. (2005)
ers, sepsis,
thrombosis,
matory disorders
Scheiﬀ et al. (2010), Hasko´ et al.
(2007), Jordan et al. (1997),
Gomez and Sitkovsky (2003),
Sullivan et al. (2004)
Yang et al. (2006)
arrhythmias Hasko´ et al. (2007), Gomez and
Sitkovsky (2003)
ssociated with
infarction,
iac transplant
Dhalla et al. (2003)
, Scheiﬀ et al. (2010), Collins et al.
(2012)
y inﬂammation Baraldi et al. (2008)
Jung et al. (2004), Baraldi et al.
(2003), Avila et al. (2002)
250 S. Sachdeva, M. Guptaconditions, as well as cancer whereas the antagonism is useful
in the treatment of Parkinson’s disease and congestive heart
failure for which selective antagonists are already in clinical tri-
als (Brand, 2007).
Various adenosine receptor ligands have been developed.
Almost all known AR agonists are derivatives of the cognate
ligand, whereas antagonists are more diverse (Carlsson et al.,
2010).
Animal models, with genes either over-expressed or deleted
have now been created in attempts to elucidate the roles of all
four adenosine receptors. Various therapeutic targets for all
the adenosine receptors are as follows:
3.1. Immunomodulatory activity
The fact that the distinct adenosine receptors can selectively
regulate discrete macrophage functions make adenosine recep-
tors a promising target for pharmacological interventions in a
wide range of disease states that involve macrophage activa-
tion e.g., protective effects of adenosine receptor stimulation
(mainly A2A and A3) have been observed in models of ische-
mia–reperfusion as well as autoimmune diseases such as rheu-
matoid arthritis, multiple sclerosis, colitis, and hepatitis
(Hasko´ et al., 2007).
Ezeamuzie and Khanin 2007 found that the inhibition of
TNF-a release by adenosine is mediated by the A2A receptors
whereas the enhancement of PGE2 release appears to be med-
iated by the A2B receptors. In mouse peritoneal cavity they
found that both the non-selective agonist NECA and the selec-
tive A2A receptor agonist CGS 21680 were more potent than
the A1 and the A3 receptor agonists, CPA and IB-MECA,
respectively suggesting that the A2 receptors are responsible
for the inhibitory effect of adenosine on TNF-a release rather
than the A1 and A3 receptors. This suggests that the A2A recep-
tor sub-type is the key receptor mediating the inhibitory effect
of adenosine on TNF-a production in this model (Ezeamuzie
and Khan, 2007).
3.2. Anti-inﬂammatory activity
A2A agonist CGS 21680 inhibits neutrophil accumulation and
protects the heart from reperfusion injury (Jordan et al., 1997).
Many recent studies indicate that adenosine acting on A2A
receptors can powerfully inhibit inﬂammation and protects tis-
sues from injury by reducing inﬂammation during reperfusion
injury. Anti-inﬂammatory properties of adenosine were shown
in many animal models of inﬂammation.
Yang et al. in 2006 found the prominent role of A2B AR
in attenuating inﬂammation, at baseline or in response to
endotoxin treatment, by regulating pro inﬂammatory cyto-
kine production and adhesion properties of the vasculature
by using adenosine receptor-null mouse models. These ef-
fects were primarily mediated via signals from hematopoietic
cells to the vasculature. Contrary to the speculated function
of A2BAR in vasodilation, the A2BAR-null mice have nor-
mal BP at baseline or in response to adenosine infusion
(Yang et al., 2006).
Gomez and Sitkovsky in 2003 demonstrated that A2A and
A3 adenosine receptors are differentially utilized by inosine
for the down-regulation of tissue damage under different
inﬂammatory conditions in vivo. Inosine, which can interactand stimulate A3 and A2 adenosine receptors, has been shown
to be protective in both concanavalin (ConA) induced fulmin-
ant hepatitis and lipopolysaccharide (LPS) induced endotoxe-
mia by inhibiting the production of pro inﬂammatory
cytokines (Gomez and Sitkovsky, 2003). A3R is essential for
protection against ConA-induced fulminant hepatitis since
only A3R-expressing mice were protected by inosine whereas
wild-type and A2AR-deﬁcient mice exhibited severe liver dam-
age even after administration of inosine. Studies in knockout
mice for either A2A receptors, A3 receptors or both revealed
that the A3-receptor subtype was necessary for protection in
the ConA-induced hepatitis model, whereas the protective ef-
fect in the LPS induced endotoxemia model was mediated by
both, the A2A and the A3 receptor subtypes (Gomez and Sit-
kovsky, 2003).
The A2B receptor antagonist, CVT-6883 had been used in
laboratory studies and also showed the inhibition of pulmon-
ary inﬂammation and injury in adenosine deaminase deﬁcient
mice and in a mouse model of bleomycin-induced pulmonary
ﬁbrosis (Baraldi et al., 2008).
A2AR agonists and antagonists can intervene inﬂammation
by enforcing and blocking A2AR dependent immunomodula-
tory mechanism (Ohta and Sitkovsky, 2009).
3.3. Cardiovascular disorders
The A1 receptor is potential therapeutic target for a number of
disorders including atrioventricular (AV) node block and
supraventricular tachyarrhythmia (adenosine agonist); AV
block of cardiac arrest (adenosine antagonist); bradyarrhyth-
mias in transplanted hearts (adenosine antagonists); diuresis
(adenosine antagonists) (Dhalla et al., 2003).
In patients with documented paroxysmal supraventricular
tachycardias involving the AV node, 99% are successfully ter-
minated with standard doses of adenosine (Strickberger et al.,
1997).
Ellenbogen et al. in 2005 found that tecadenoson is a potent
selective A1-adenosine receptor agonist with a dose-dependent
negative dromotropic effect on the AV node. They evaluated
tecadenoson (6-[N-30-(R)-tetrahydrofuranyl]-amino-purine
riboside, formerly CVT-510), a selective A1-adenosine agonist,
for the acute termination of PSVT. In the atrial-paced guinea
pig heart model, tecadenoson caused an A1-adenosine recep-
tor-mediated negative dromotropic effect on the AV node
and lengthening of the AV nodal refractory period, leading
to termination of reentrant PSVT at doses that did not affect
blood pressure (BP), sinus cycle length, or the His-ventricular
interval. Side effects mediated by the A2A-, A2B-, and A3-aden-
osine receptors such as ﬂushing, chest pressure, hypotension,
and bronchospasm were infrequent, consistent with the A1-
adenosine receptor selectivity of the drug (Ellenbogen et al.,
2005).
3.4. Bacterial sepsis
AR agonists increase mouse survival in endotoxemia and sep-
sis via A2A AR-mediated mechanisms and reduce the number
of live bacteria in blood. In a bacterial sepsis model (Esche-
richia coli) treatment with an A2A-receptor agonist ATL-146e
in combination with antibiotic therapy increased survival from
40% to 100%. The protective effects of both ATL146e and
Adenosine and its receptors as therapeutic targets: An overview 251IB-MECA were counteracted by the A2A AR selective antago-
nist 4-(2-[7-amino-2-furyl][1,2,4]triazolo[2,3-a][1,3,5]triazin-5-
yl-amino]ethyl)-phenol (Sullivan et al., 2004).3.5. Asthma and glaucoma
The potent adenosine A3 receptor antagonists have been devel-
oped for therapeutic treatment of inﬂammatory diseases such
as asthma and glaucoma (Jung et al., 2004). Activation of A3
receptors has been shown to stimulate phospholipase C and
to inhibit adenylate cyclase. A3 agonists also cause stimulation
of phospholipase D and the release of inﬂammatory mediators,
such as histamine from mast cells, which are responsible for
inﬂammation and hypotension. For these reasons, the clinical
use of A3 adenosine receptor antagonists for the treatment of
asthma and inﬂammatory disease has been suggested (Baraldi
et al., 2003).
A3 adenosine receptors also contribute to the regulation of
intraocular pressure (IOP). Avila et al. in 2002 found the IOP
responses to adenosine, A3AR agonists and A3AR antagonists
using A3-knockout (A3AR
/) and A3AR
+/+ control mice by
the servo-null approach. The IOP was signiﬁcantly lower in
A3AR
/ mice (12.9 ± 0.7 mm Hg) than in A3AR
+/+ control
animals (17.4 ± 0.6 mm Hg). The nonselective AR agonist
adenosine produced a much smaller increase in IOP
(2.2 ± 0.8 mm Hg) in the knockout than in A3AR
+/+ control
mice (14.9 ± 2.4 mm Hg). The A3-selective agonist IB-MECA
did not affect IOP in A3-knockout mice, but raised it in
A3AR
+/+ mice. The highly selective A3AR antagonist MRS
1191 did not affect IOP in A3AR
/ mice, but lowered it in
A3AR
+/+ control mice. The nonselective agonist adenosine
increased IOP in the knockout mice by 2.2 ± 0.8 mm Hg at
an applied droplet concentration of 100 lM and by
5.8 ± 1.8 mm Hg at a concentration of 2 mM. The highly
selective antagonist of both human and murine A3ARs MRS
1191(25 lM) had no effect on baseline IOP in the A3AR
/
mice. In contrast, MRS 1191 at the same concentration re-
duced IOP in the A3AR
+/+ C57Bl/6 mice by
7.0 ± 0.9 mm Hg (Avila et al., 2002).3.6. CNS disorders
Several pharmacological studies suggest that the A2A receptor
is involved in motor activity. In particular, adenosine A2A
receptor antagonists have been demonstrated to restore the
deﬁcits caused by degeneration of the striatonigral dopamine
system, and therefore offer a possible treatment for Parkin-
son’s disease (Zhang et al., 2008).
Antagonists of the A2A subtype of adenosine receptor have
emerged as a leading candidate class of nondopaminergic anti-
parkinsonian agents (Feigin, 2003). The ability of Lu
AA47070, adenosine A2A antagonist to reverse the effects of
D2 receptor blockade suggests that this compound could have
potential utility as a treatment for parkinsonism, and for some
of the motivational symptoms of depression. In the adult male
Sprague Dawley rats the tremulous jaw movements induced by
subchronic administration of the DA D2 antagonist pimozide
were reversed by Lu AA47070. Lu AA47070 was also able to
reverse the catalepsy induced by subchronic administration
of the D2 antagonist pimozide and it also reverse the locomo-tor suppression induced by subchronic administration of the
D2 antagonist pimozide (Collins et al., 2012).
Currently the main approach used in clinical trials involves
the co-administration of A2AR antagonists with L-DOPA. The
proposed advantage of this strategy is a reduction in the re-
quired dose of L-DOPA, with concomitant reductions in the
associated side effects, consisting mainly of dyskinesias and
progressive cognitive impairment (Armentero et al., 2011).
Adenosine as a contributing element in the pathophysiol-
ogy of schizophrenia embraces several neurotransmitter sys-
tems and brain regions due to its multiple and widespread
modulatory actions (Lara et al., 2006).
Adenosine also plays a very important role in the regulation
of immune response during pathogenesis of AIDS. Barat et al.
in 2008 found that extracellular ATP can act as a factor con-
trolling HIV-1 propagation. They showed that extracellular
ATP reduces HIV-1 transfer from immature monocyte-derived
DCs (iDCs) to autologous CD4+ T cells. This observed de-
crease in viral replication was related to a lower proportion
of infected CD4+ T cells following transfer, and was seen with
both X4- and R5-tropic isolates of HIV-1. Extracellular ATP
had no effect on direct CD4+ T cell infection as well as on pro-
ductive HIV-1 infection of iDCs. These observations indicate
that extracellular ATP affects HIV-1 infection of CD4+ T cells
in trans with no effect on de novo virus production by iDCs.
HIV-1 associated dementia is a major problem in patients
suffering from AIDS. This occurs due to the direct toxic effect
of viral proteins on neuronal cells and indirectly by the release
of proinﬂammatory mediators and neurotoxins by activated
macrophages/microglia and astrocytes, causing apoptosis of
neuronal cells (Barat et al., 2008).
4. Conclusion
The objective of this article is to highlight the exploration of
adenosine receptors and to illustrate their potential as ther-
apeutic agents to treat an impressively wide range of
diseases.
From the above discussion, it has been concluded that
adenosine is a purine ribonucleoside which has the properties
of neuromodulator as well as neurotransmitter and it displays
a wide range of biological activities. Effects of adenosine are
mediated by membrane bound receptors, which are linked to
G-proteins. Adenosine concentrations appear to be low during
resting conditions, but can be substantially elevated during hy-
poxia and ischemia and by increased mechanical and biochem-
ical work.
These receptors are currently investigated as drug targets,
for example, for the treatment of cardiovascular disorders, re-
nal diseases, hypertension, Parkinson’s disease, Alzheimer’s
disease, asthma, chronic obstructive pulmonary disease
(COPD), inﬂammatory and allergic disorders and cancer.
Great strides have thus been made over the past few years
to exploit the biological properties of adenosine, and we now
have in hand an impressive number of promising adenosine
based drug candidates for treatment of various dreadful dis-
eases like rheumatoid arthritis, asthma, cancer and various
CNS disorders like Parkinson’s disease.
There is every reason to believe that new and important
therapeutic applications of adenosine ligands are just waiting
to be discovered.
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